Lexicon Pharmaceuticals
Manufacturing · Texas, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
2445 Technology Forest Blvd Fl 11, The W...Phone Number
(281) 863-3000Website
www.lexpharma.comRevenue
$41.5 MillionStock Symbol
LXRXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals is a biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for people with serious, chronic conditions. Using a patient driven approach, we are working to discover and develop innovative medicines to safely and effectively treat disease and improve patient lives.Explore more
Lexicon Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lexicon Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Lexicon Pharmaceuticals has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Lexicon Pharmaceuticals is spiking on competitors!
Lexicon Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Lexicon Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Lexicon Pharmaceuticals
Click to see if Lexicon Pharmaceuticals had a recent Job posting/layoffs
Product Launch: Get notified when Lexicon Pharmaceuticals launches new products
Earning: See what the market has to say on Lexicon Pharmaceuticals recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Lexicon Pharmaceuticals as Masked Content
Find more new buyers
Compare Similar Companies to Lexicon Pharmaceuticals
Compare insights from companies similar to Lexicon Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Lexicon Pharmaceuticals
$41.5M
51-200
Public
$1.5B
1995
Scott CoianteSenior Vice President & Chief Financial Officer
$232.4M
51-200
Public
$155M
2007
EO
Erik OstrowskiSenior Vice President, Chief Financial Officer and Chief Business Officer
Company Profile Activity
Activity Insights
Lexicon Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Lexicon Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Lexicon Pharmaceuticals.
Lexicon Pharmaceuticals financials insights
Gather financial insights about Lexicon Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2009
Stock Offering
$55.2M
2010
Stock Offering
$181.4M
2012
Stock Offering
$37.2M
2014
Multiple Rounds
$273.7M
2017
Debt
$200M
2022
Debt
$150M
2026
Stock/Share Issuance
$55.7M
Lexicon Pharmaceuticals Tech Stack
A closer look at the technologies used by Lexicon Pharmaceuticals
See more technologies
Most Recent Scoops
Partnership
Lexicon Pharmaceuticals has entered into a licensing arrangement with Viatris, under which Viatris has obtained regulatory approval for sotagliflozin in heart failure in the United Arab Emirates and Bahrain, and has submitted applications for regulatory approval in more than a dozen additional countries, including Saudi Arabia, Canada, and Australia. Viatris anticipates regulatory decisions in Australia and Canada, as well as additional regulatory submissions in other markets, during the current year.
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Project
Lexicon Pharmaceuticals has announced a successful end of Phase II meeting with the FDA for pilavapadin in diabetic peripheral neuropathic pain, receiving guidance that supports commitment to a Phase III program, with the FDA formally recognizing pilavapadin's lack of addiction potential a significant distinction in a therapeutic area where oral opioids account for approximately 20% of the current treatment regimen.
Pharmaceuticals, Clinical Operations
Project
Lexicon Pharmaceuticals News & Media
Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure
Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart FailureLexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
LX9851 is a first-in-class, oral non-incretin candidate being developed by Novo Nordisk for the treatment of obesity and associated metabolic disordersLexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
Enrollment complete in Phase 3 SONATA-HCM study; top-line data expected Q1 2027
Read more news
Top Manufacturing Companies
Frequently Asked Questions Regarding Lexicon Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Lexicon Pharmaceuticals is a biopharmaceutical company that is applying a unique approach to gene science based on Nobel Prize-winning technology to discover and develop precise medicines for people with serious, chronic conditions. Using a patient driven approach, we are working to discover and develop innovative medicines to safely and effectivel... Read More
